Portfolio Lab

Immunocore Holdings plc

  • Stock
  • Ticker IMCR
  • ISIN US45258D1054
  • Nasdaq
  • US listing in dollars (ADR)

Health care · Biotechnology · Other countries

$26.41 −0.83%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Immunocore Holdings plc since 02/2021, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

IMCRGlobal equities (VT)

$10,000 grew to $6,856. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −67.4% in 04/2025, measured from the peak in 02/2024. The old peak has not been reached again yet.

1-year return
−32.3%
5-year return p.a.
−7.1%
Return p.a. since 02/2021
−8.2%
Volatility p.a.
47.8%
Largest decline
−67.4%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue849498104104107116102
Gross profit849397103102106115102
Operating income-19-3.6-15-7.2-207.3-3.0-14
EBITDA-18-2.8-14-6.4-198.2-2.0-13
Net income-245.0-10-0.2-3013-0.8-14
Earnings per share-0.470.10-0.200.00-0.600.25-0.02-0.28
Balance sheet
Total assets1,0101,0281,0821,1031,0671,0721,1191,129
Liabilities649650694706686678700710
Equity361378388397381394420420
Cash456477488498468453485512
Cash flow
Operating cash flow-140.426-4.5-33-141620
Capital expenditure-3.6-0.3-0.4-0.7-2.9-1.8-0.8-2.3
Free cash flow-180.126-5.2-36-161518

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2022 at +66.7%, weakest 2024 at −56.8%. 3 of 4 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
6 Nov 2026−$0.28
6 Aug 2026−$0.02
6 May 2026$0.25
25 Feb 2026−$0.60
6 Nov 2025$0.00
7 Aug 2025−$0.20
7 May 2025$0.10
26 Feb 2025−$0.47
6 Nov 2024$0.17
8 Aug 2024−$0.23

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.2bn
Market cap in trading currency
$1.36bn
Enterprise value
$464m
P/E
–
P/S
3.18
P/B
3.25
EV/Sales
1.08
EV/EBITDA
–
Earnings yield
–
FCF yield
-1.3%

Results (last four quarters)

Revenue
$429m
Gross profit
$424m
EBITDA
−$25.3m
Net income
−$32.1m
Earnings per share
−$0.65
Revenue per share
$8.31
Revenue growth
−1.4%
Earnings growth
–

Profitability

Gross margin
98.9%
Operating margin
-6.8%
Net margin
-7.5%
Return on equity
-7.9%
Return on assets
-2.8%

Balance sheet and cash flow

Cash
$901m
Cash per share
$17.44
Financial debt
–
Debt/equity %
–
Current ratio
4.62
Book value per share
$8.12
Operating cash flow
−$10.4m
Free cash flow
−$18.2m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
51.7m
Volume
546,182
Avg. volume 3 months
464,423
Relative volume
1.2

Price and technicals

Price
$26.41
1 day
−0.8%
52-week high
$40.22
52-week low
$26.41
Distance to 52-week high
−34.3%
Distance to 52-week low
0.0%
Distance to 50-day line
−13.0%
Distance to 200-day line
−16.1%
RSI (14)
33
Volatility 1M
50.0%

Performance

1 week
−11.8%
1 month
−17.8%
3 months
−27.9%
6 months
−8.4%
YTD
−23.9%
1 year
−31.7%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has IMCR performed since 02/2021?

$10,000 grew to $6,113 by 20 Nov 2026, which is −8.2% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is IMCR?

Volatility was 47.8% per year, measured on monthly returns. The largest decline from a peak was −67.4%, with the low in 04/2025.

How does IMCR compare with a broad equity ETF?

Over the same period Global equities (VT) returned +8.9% per year at 14.7% volatility, IMCR returned −8.2% at 47.8%. The correlation of monthly returns was 0.26; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's depositary receipt (ADR) traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Immunocore Holdings plc (IMCR): Return and risk